In a landmark development for the biotech industry, Novartis has inaugurated its first European facility dedicated to the production of viral vectors in Mengeš, just north of Ljubljana.
The €40 million investment brings state-of-the-art automation and robotics to the heart of Slovenia, supporting the production of viral vectors essential for revolutionary cell and gene therapies aimed at treating autoimmune and genetic disorders, as well as cancer.
The facility, VIFA One, solidifies Slovenia’s position as a key player in the global biotech ecosystem, as it collaborates with academic and research institutions to advance innovation.
With over 3,900 employees in the country, Novartis’ presence continues to grow, supported by significant government initiatives in research, higher education, and sustainable technologies.
The investment underpins the company’s broader strategy to cement its leadership in life sciences while accelerating Slovenia’s role in global health solutions.
